ABBVIE
A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 36
- Registration Number
- NCT03441555
- Locations
- 🇩🇪
Univ Klinik Eppendorf Hamburg /ID# 168633, Hamburg, Germany
🇺🇸NYU Langone Medical Center /ID# 201559, New York, New York, United States
🇺🇸University of Pittsburgh Medic /ID# 170790, Pittsburgh, Pennsylvania, United States
UNITE Study: Understanding New Interventions With GBM ThErapy
- Conditions
- Glioblastoma Multiforme
- Interventions
- Drug: Steroid eye dropsDrug: Vasoconstrictor eye dropsDrug: Depatuxizumab mafodotinOther: Cold compressDrug: TemozolomideRadiation: RadiationDrug: Ophthalmic steroid ointment
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 40
- Registration Number
- NCT03419403
- Locations
- 🇩🇪
Universitatsklinikum Tubingen /ID# 169965, Tuebingen, Germany
🇺🇸Levine Cancer Ins, Carolina Me /ID# 171271, Charlotte, North Carolina, United States
🇳🇱Vrije Universiteit Medisch Centrum /ID# 170152, Amsterdam, Netherlands
Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic Leukemia
- Conditions
- Cancer - Chronic Lymphocytic Leukemia
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 269
- Registration Number
- NCT03415035
- Locations
- 🇫🇷
Ch Agen /Id# 170742, Agen Cedex 9, France
🇫🇷CH Victor Dupouy /ID# 169946, Argenteuil, France
🇫🇷CH Libourne - Hopital Robert Boulin /ID# 170739, Libourne, France
Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104
- Conditions
- Progressive Supranuclear Palsy (PSP)
- Interventions
- Drug: ABBV-8E12
- First Posted Date
- 2018-01-29
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 3
- Registration Number
- NCT03413319
- Locations
- 🇺🇸
University of California, San /ID# 170113, La Jolla, California, United States
🇺🇸Texas Health Physicians Group /ID# 170112, Dallas, Texas, United States
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
- Conditions
- Small Lymphocytic Lymphoma (SLL)Chronic Lymphocytic Leukemia (CLL)
- Interventions
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT03406156
- Locations
- 🇺🇸
Oncology Hematology Care, Inc. /ID# 202397, Cincinnati, Ohio, United States
🇺🇸Tennessee Oncology-Nashville Centennial /ID# 201098, Nashville, Tennessee, United States
🇺🇸Arizona Oncology Associates, PC-HOPE /ID# 202335, Tempe, Arizona, United States
A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
- Conditions
- Cancer - Ovarian
- Interventions
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- AbbVie
- Registration Number
- NCT03400306
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
- Conditions
- Ulcerative Colitis (UC)
- Interventions
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1242
- Registration Number
- NCT03398135
- Locations
- 🇺🇸
Cedars-Sinai Medical Center /ID# 163848, Los Angeles, California, United States
🇺🇸UCSF Medical Center - Mount Zion /ID# 201209, San Francisco, California, United States
🇺🇸Duplicate_Medical Research Center of CT /ID# 160287, Hamden, Connecticut, United States
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Ulcerative Colitis (UC)
- Interventions
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1558
- Registration Number
- NCT03398148
- Locations
- 🇿🇦
Private Practice Dr MN Rajabally /ID# 171137, Cape Town, Western Cape, South Africa
🇺🇸Massachusetts General Hospital - Crohn's and Colitis Center /ID# 164255, Boston, Massachusetts, United States
🇺🇸Cedars-Sinai Medical Center-West Hollywood /ID# 163851, West Hollywood, California, United States
An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
- Conditions
- Progressive Supranuclear Palsy (PSP)
- Interventions
- Drug: ABBV-8E12Drug: Placebo solution for IV infusion on Day 15
- First Posted Date
- 2018-01-05
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 142
- Registration Number
- NCT03391765
- Locations
- 🇺🇸
Usc /Id# 165529, Los Angeles, California, United States
🇺🇸University of California, Los Angeles /ID# 165669, Los Angeles, California, United States
🇮🇹IRCCS San Camillo /ID# 201229, Venice, Italy
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
- Conditions
- Blastic Plasmacytoid Dendritic Cell NeoplasmMyeloproliferative Neoplasm
- Interventions
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 179
- Registration Number
- NCT03386513
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, Washington, United States